The announcement of the success of the first vaccine against melanoma sends Moderna and Merck shares soaring
The breakthrough has been publicized in a press release that does not provide specific data on improved survival rates. If confirmed, this would be a historic milestone.
Moderna and MSD (Merck) have announced that their phase 3 trial of a personalized melanoma vaccine has achieved success. The trial combined the vaccine, known as intismeran autogene, with the immunotherapy pembrolizumab. The companies reported that the combination reached its objectives for recurrence-free survival and preventing cancer from spreading to other organs. Moderna's shares rose up to 87% and MSD's shares rose up to 8% following the announcement.
Written by urgent.news from El Pais's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
